Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Sold by Verition Fund Management LLC

Verition Fund Management LLC cut its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 35.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 5,135 shares of the company’s stock after selling 2,821 shares during the quarter. Verition Fund Management LLC’s holdings in Kymera Therapeutics were worth $243,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of KYMR. FMR LLC increased its holdings in shares of Kymera Therapeutics by 5.8% during the 3rd quarter. FMR LLC now owns 5,109,141 shares of the company’s stock valued at $241,816,000 after purchasing an additional 282,301 shares in the last quarter. Jennison Associates LLC increased its holdings in Kymera Therapeutics by 85.8% in the third quarter. Jennison Associates LLC now owns 797,681 shares of the company’s stock valued at $37,754,000 after buying an additional 368,394 shares in the last quarter. Massachusetts Financial Services Co. MA raised its position in shares of Kymera Therapeutics by 11.7% in the third quarter. Massachusetts Financial Services Co. MA now owns 453,377 shares of the company’s stock worth $21,458,000 after acquiring an additional 47,507 shares during the period. Dimensional Fund Advisors LP grew its position in shares of Kymera Therapeutics by 15.2% during the 2nd quarter. Dimensional Fund Advisors LP now owns 402,385 shares of the company’s stock valued at $12,012,000 after acquiring an additional 53,176 shares during the period. Finally, Driehaus Capital Management LLC purchased a new position in shares of Kymera Therapeutics in the 2nd quarter valued at about $6,669,000.

Insider Activity

In other news, Director Pamela Esposito sold 13,500 shares of the business’s stock in a transaction dated Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total transaction of $651,780.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 15.82% of the company’s stock.

Kymera Therapeutics Stock Down 0.1 %

NASDAQ:KYMR opened at $42.13 on Monday. The stock’s fifty day moving average is $46.25 and its two-hundred day moving average is $42.99. Kymera Therapeutics, Inc. has a 52 week low of $22.35 and a 52 week high of $53.27. The stock has a market capitalization of $2.73 billion, a price-to-earnings ratio of -18.00 and a beta of 2.16.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings results on Thursday, October 31st. The company reported ($0.82) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.01. The company had revenue of $3.74 million during the quarter, compared to the consensus estimate of $10.34 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The firm’s quarterly revenue was down 20.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.90) earnings per share. On average, sell-side analysts expect that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have commented on the company. UBS Group dropped their price objective on Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating on the stock in a report on Monday, November 4th. BTIG Research assumed coverage on shares of Kymera Therapeutics in a report on Tuesday, December 10th. They issued a “buy” rating and a $60.00 price target for the company. Stephens began coverage on shares of Kymera Therapeutics in a report on Monday, November 18th. They set an “overweight” rating and a $65.00 price objective on the stock. Wells Fargo & Company raised shares of Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $38.00 to $57.00 in a research note on Monday, December 2nd. Finally, Truist Financial reaffirmed a “buy” rating and issued a $53.00 price target (down from $54.00) on shares of Kymera Therapeutics in a research note on Friday, November 1st. Four research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $53.88.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.